StocksMedium•9 November 2026•
1 min read
Tonix Pharmaceuticals Reports 37% Sequential Growth in TONMYA Sales for Q3 2026
Key Facts
1Tonix Pharmaceuticals reported Q3 TONMYA net sales of approximately $15 million, a 37% increase from the second quarter.
2The company held approximately $163 million in cash and cash equivalents as of September 30, 2026.
Tonix Pharmaceuticals reported Q3 2026 net sales for its TONMYA product of approximately $15 million, marking a 37% increase over the previous quarter. According to GlobeNewswire, the company held approximately $163 million in cash and cash equivalents as of September 30, 2026.
TNXP closed at $4.74 on November 6, 2026, with the stock trading between a low of $4.63 and a high of $4.83 during that session. These financial results highlight the company's sequential sales momentum and its current liquidity position as it manages its pharmaceutical portfolio.